<DOC>
	<DOCNO>NCT00073970</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may stop growth cancer stop blood flow tumor block enzyme necessary tumor cell growth . PURPOSE : Phase II trial study effectiveness celecoxib treat patient relapsed prostate cancer follow radiation therapy radical prostatectomy .</brief_summary>
	<brief_title>Celecoxib Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy Radical Prostatectomy</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect celecoxib prostate-specific antigen ( PSA ) level patient prostate cancer biochemical relapse prior definitive radiotherapy radical prostatectomy . - Compare PSA double time patient treated drug v historical control . - Compare PSA double time patient treated drug v pretreatment PSA value . - Determine time clinical recurrence patient treat drug . OUTLINE : Patients receive oral celecoxib twice daily . Treatment continue 5 year absence disease progression . Patients may continue treatment beyond 5 year discretion treat physician . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis clinically localize adenocarcinoma prostate T1 T2 disease Received prior primary treatment definitive radiotherapy ( least 5,500 cGy ) OR radical prostatectomy Biochemical relapse within 5 year prior primary therapy , define 1 following : Detectable rise prostatespecific antigen ( PSA ) surgery ( least 2 value residual cancer detection limit assay ) PSA least 2 value 1 ng/mL OR least 3 rise value level radiotherapy PSA great 10 ng/mL PATIENT CHARACTERISTICS : Age Not specify Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic ALT great 2.5 time upper limit normal Renal Creatinine normal Other No allergy cyclooxygenase2 inhibitor , aspirin , nonsteroidal antiinflammatory drug , sulfa drug No untreated peptic ulcer disease PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy More 6 month since prior adjuvant neoadjuvant hormonal therapy Duration prior adjuvant neoadjuvant hormonal therapy must 6 month Radiotherapy See Disease Characteristics Prior salvage radiotherapy prostatectomy allow Surgery See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>